New data on PM1183 sees a response rate of 36 percent as single agent in patients with SCLC
Madrid, September 12th, 2017.- PharmaMar (MSE:PHM) has presented today during the European Society for Medical Oncology congress (ESMO), held in Madrid, positive results of PM1183...



